reducing cardiovascular risk: an emphasis on rosuvastatin
Clicks: 269
ID: 200220
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
269 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #7 of 17 articles by views in pediatric urology case reports
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Rosuvastatin is one of the most frequently prescribed drugs for primary and secondary prevention of myocardial infarction and stroke. The present article deals with the main studies confirming the effectiveness of rosuvastatin in patients with different cardiovascular risks.
| Reference Key |
g.s.2017reducing
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Anikin G.S.;Storozhuk I.K.;Filyazova Ya.Yu. |
| Journal | pediatric urology case reports |
| Year | 2017 |
| DOI |
10.26442/2075-082X_14.4.50-54
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.